Examining Mu Opioid Mechanisms of Ketamine's Rapid Effects in OCD (MKET2)
Stanford University
150 participants
Feb 24, 2024
INTERVENTIONAL
Conditions
Summary
The purpose of this study is to understand how ketamine works in the brain to bring about a reduction in OCD symptoms.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Ketamine is an FDA-approved dissociative anesthetic.
Naltrexone is an oral opioid antagonist approved by the Food and Drug Administration (FDA) to treat both alcohol use disorder (AUD) and opioid use disorder (OUD)
An oral inactive placebo pill will be administered to preserve the blinded nature of the study.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05940324